Skip to main content
Evidence Snapshot

CEM-SS

CHEMBL614548 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614548
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats CEM-SS as ChEMBL target CHEMBL614548. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
CEM-SS
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614548
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why CEM-SS matters

As of 2026-09-13

CEM-SS is reviewed as CEM-SS; the current evidence base includes 13 approved drugs, 1492 compounds, and 460 assays, with lead potency reaching pChEMBL 10.6.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 13 approved drugs, 1492 compounds, and 460 assays for this target. The dominant activity type is IC50. CHEMBL336441 is the current potency anchor at pChEMBL 10.6.

Use CHEMBL336441 as the tractability anchor when discussing potency (pChEMBL 10.6).

Activity source · ChEMBL 36 via Core Engine
13 approved pChEMBL 10.6
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why CEM-SS matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1492
Total Compounds
460
Total Assays
13
Approved Drugs
IC50: 525.0, EC50: 422.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL336441
 10.6 EC50 —
No preferred name
CHEMBL137838
 10.2 EC50 —
No preferred name
CHEMBL344257
 10.1 EC50 —
No preferred name
CHEMBL141223
 9.9 EC50 —
No preferred name
CHEMBL138969
 9.8 EC50 —

Approved Drugs

Structure Compound First Approval
PLERIXAFOR
CHEMBL18442
 2008
ADEFOVIR DIPIVOXIL
CHEMBL922
 2002
GEMCITABINE
CHEMBL888
 1996
SAQUINAVIR
CHEMBL114
 1995
STAVUDINE
CHEMBL991
 1994
ZALCITABINE
CHEMBL853
 1992
ZIDOVUDINE
CHEMBL129
 1987
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:01Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614548